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ABSTRACT
Introduction and objectives: coeliac disease (CD) and its cuta-
neous manifestation, dermatitis herpetiformis are both (DH) gluten-
sensitive diseases. Metabolic bone disease is common among patients
with CD, even in asymptomatic forms. Data are scarce about bone
density in patients with dermatitis herpetiformis. The aim of our
study was to compare bone mineral density (BMD) of celiac and der-
matitis herpetiformis patients.
Methods: 34 coeliac patients, 53 with dermatitis herpetiformis
and 42 healthy controls were studied. The mean age was 38.0 ±
12.1, 32.18 ± 14.95, 35.33 ± 10.41 years in CD, dermatitis
herpetiformis, and healthy controls, respectively. Bone mineral
density of the lumbar spine, the left femoral neck and radius were
measured by dual-energy X-ray absorptiometry. Low bone density,
osteopenia and osteoporosis were defined as a body mass density
(BMD) T-score between 0 and -1, between -1 and -2.5, and under
-2.5, respectively.
Results: at lumbar region, consisting of dominantly trabecular
compartment, a decreased BMD was detected in 49 % (n = 26)
patients with dermatitis herpetiformis, 62 % (n = 21) of CD patients,
and 29 % (n = 12) of healthy controls, respectively. Lower BMD
were measured at the lumbar region in dermatitis herpetiformis and
CD compared to healthy subjects (0.993 ± 0.136 g/cm2 and 0.880
± 0.155 g/cm2 vs. 1.056 ± 0.126 g/cm2; p < 0.01). Density of
bones consisting of dominantly cortical compartment (femoral neck)
did not differ in dermatitis herpetiformis and healthy subjects.
Conclusions: our results show that a low bone mass is also fre-
quent among patients with dermatitis herpetiformis. Bone mineral
content in these patients is significantly lower in those parts of the
skeleton which contain more trabecular than cortical bone.
Key words: Dermatitis herpetiformis. Coeliac disease. Osteoporo-
sis. Bone mineral density.
INTRODUCTION
Dermatitis herpetiformis (DH), or Duhring’s disease is
a chronic blistering skin condition, characterised by vesi-
cles filled with a watery fluid on the extensor surfaces of
the elbows, buttocks and knees (1). The name herpeti-
formis derives from the fact that the vesicles manifest as
small dense clusters similar to those seen in herpes sim-
plex. Dermatitis herpetiformis is linked to gluten sensi-
tivity and has a clear relationship to coeliac disease (CD),
but enteropathy is usually less severe than that found in
patients with CD (2).
The most common age at onset of the DH symptoms
is between the 3rd and 4th decades. Interestingly, males
have a higher prevalence of DH (1.5-2:1) unlike CD (1:2-
4) (3). Both diseases show strong genetic predisposition:
the incidence of DH and CD among first-degree relatives
is about 15 times higher than in the general population
(4), and a close association between DH and human leuko-
cyte antigen-DQ2 or DQ8 (5,6) has been reported, such
as in CD (7).
Transglutaminase (TG) plays a central role in gluten
intolerance. Tissue TG is the major autoantigen for CD,
which is a ubiquitous molecule in many tissues (8,9). In
patients with DH, epidermal TG also appears to be the dom-
inant autoantigen. It is homologous to tissue TG within the
enzymatically active domains and its main function in the
epidermis to save the integrity of the skin. The expression
of epidermal TG is primarily seen in the epidermis and
small intestine (10,11).
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Gluten-free diet (GFD) is the basis of the therapy in both
DH and CD. A gluten challenge causes flares of the cuta-
neous symptoms. Adherence to GFD not only reduces skin
symptoms, malabsorption and villous atrophy, but also
decrease the risk of small bowel lymphoma.
It is well known that both diseases have associations
with other extraintestinal diseases, mainly of autoimmune
type. Moreover, CD associates with metabolic bone disease.
The frequency of low bone mineral density (BMD) among
coeliac patients varies widely between different studies due
to differences in diagnostic criteria, geographical distribu-
tion and patient selection (12-14). The presence of signif-
icant malabsorption leads to a more severe bone loss in CD
(15), although BMD is lower in asymptomatic patients com-
pared to healthy subjects, as well (16).
The fracture rate was observed to be high in CD patients
compared to controls in a recent meta-analysis including
data of more than 20,000 subjects (8.7 vs. 6.1 %; pooled
odds ratio: 1.43; 95 % confidence interval 1.15-1.78) (17).
There are only a few small studies in the literature con-
sidering bone metabolism in DH patients. Moreover, these
observations have provided conflicting data regarding BMD
in DH, so the need for further studies to determine the frac-
ture risk in DH is clear. This study aims to compare the
bone density of DH patients to CD and healthy controls.
METHODS
Fifty-three DH and 34 CD patients were enrolled from
the outpatient gastroenterology clinic of the 2nd Department
of Medicine, Semmelweis University, and 42 healthy con-
trol (HC) subjects from the clinical staff taking into con-
sideration the matching of gender and age. As an inclusion
criterion, all patients and controls were adults. All coeliac
patients reported themselves as being on a gluten free diet
(GFD) since their diagnosis. There were 2 newly diagnosed
CD and 2 DH patients. Their diagnosis was confirmed
6 months before and they also were on GFD. 11.8 % of CD
patients had mild gastrointestinal symptoms (bloating or
loose stool), but there were no diarrhoea present among
them. A third of the DH patients (33 %) were not on strict
GFD. Similar ratio of DH patients (15.1 %) had abdominal
complaints, but none of them had have skin symptoms from
the 6 months previous to be recruited for this study. The
study protocol was approved by the local Ethic Committee
and the study protocol conformed to the ethical guidelines
of the Declaration of Helsinki. Following written informed
consent patients underwent osteodensitometry, upper panen-
doscopy and blood tests.
Patients suffering thyroid or primary parathyroid dys-
function or other chronic diseases were excluded from this
study. Those patients who were treated with steroids were
also excluded. Previously known metabolic diseases affect-
ing the bone metabolism was also considered as an exclu-
sion criterion. Diagnosis of DH was established in all
patients by the presence of typical clinical features and by
demonstrating granular IgA deposits in the dermal papillae
of uninvolved perilesional skin on direct immunofluores-
cence. Diagnosis of CD was established in all patients by
the presence of clinical features, anti-endomysium antibody
(EMA) serology and small intestinal histology.
Serum levels of calcium (Ca), phosphorous and albumin
were measured in every study subject. EMAs were assessed
by indirect immunofluorescence on monkey oesophageal
sections by using fluorescein isothiocyanate and antihuman
IgA as secondary antibody.
Small bowel biopsies were also performed in the DH group
at the moment of diagnosis; specimens were stained with
hematoxylin-eosin and investigated via light microscopy. The
grading system based on Marsh-Oberhuber classification of
small intestinal enteropathy in CD was used to assess the his-
tological abnormalities: stage 0 –normal mucosa; stage 1 –
increased intraepithelial lymphocyte count; stage 2 –cryptal
hyperplasia and increased intraepithelial lymphocyte count;
and stage 3a-3c –mild/moderate/severe villous atrophy with
increased intraepithelial lymphocyte (18).
BMD measurements were performed by dual-energy X-
ray absorptiometry of the lumbar spine, the left femoral
neck and the non-dominant radius using a Hologic QDR
4500C instrument (Hologic©, Waltham, MA). For analysis,
software v. 9.03D was used. Z-scores (the number of stan-
dard deviations from age- and sex-matched healthy con-
trols) and T-scores (number of standard deviations from
peak bone mass, i.e. the maximum BMD value reached by
an adult) were calculated according to the manufacturer’s
reference curves. The third National Health and Nutrition
Examination Surveys normative data were used as a refer-
ence database for femoral bone density measurements.
World Health Organization criteria for low BMD were
applied for this analysis (19): osteopenia were defined as
a BMD T-score below -1 and -2.5, and osteoporosis were
defined as a BMD T-score were under -2,5. Quality control
was maintained by daily scanning of an anthropometric
spine phantom. The coefficient for the variation of BMD
measurements on the spine phantom over a period of 4
years was 0.35 % in our laboratory.
Calculations were performed using SPSS statistics 15.0
software. Paired and independent sample Student’s t-tests,
Pearson correlations were applied. The results were pre-
sented as mean ± standard deviation. Results were consid-
ered significant when p < 0.05.
RESULTS
Thirty-four coeliac patients and 53 with DH were enrolled
from the outpatient clinic of our department. Their data were
compared to 42 healthy controls in this cross sectional study.
The mean age was 38.0 ± 12.1 in CD, 32.18 ± 14.95 in DH
patients, and 35.33 ± 10.41 in healthy controls (p = NS).
8.8 % of CD, 7.4 % of DH patients and 7.1 % of HC were
postmenopausal women (p = NS). Main demographical and
clinical parameters of all groups are shown in table I.
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A lower BMD was documented at lumbar spine in both
groups of patients (DH and CD) compared to HC. Lumbar
BMD was significantly lower in CD compared to DH
patients. Femoral and radius BMD did not differ in DH
compared to HC subjects. However a lower BMD was
observed at both sites in CD patients compared to HC sub-
jects. Data of the two groups of patients and HC were com-
pared. Statistically significant differences were obtained
from all three measurement sites between CD and HC. Main
results are presented in figures 1-3.
A low BMD was observed at the lumbar spine (n = 26,
49 %) and the radius (n = 31, 58 %) of DH patients; in con-
trast, a decreased mineral density at the femoral neck was
found in a lower proportion of DH patients (n = 11, 21 %).
62 % (n = 21) and 71 % (n = 24) of celiac patients also had
a low BMD at the lumbar spine and non-dominant radius,
respectively. The proportion of low bone mass at the femoral
neck was higher (n = 17, 50 %) among CD patients. The
minority of subjects in HC group exhibited a low bone mass
(n = 2, 5 %), independently from the site of the measure-
ment. Data and significance values are detailed in table II.
Regarding to the T-score at lumbar axis, it value was -
0.855 ± 1.227 g/cm2 in patients with DH, and -1.848 ± 1.398
g/cm2 in those with CD (p < 0.001). At left femoral neck,
T-scores were 0.182 ± 1.183 g/cm2 in DH patients, and -
1.165 ± 1.295 g/cm2 in CD patients, respectively (p <
0.001). There were no significant differences between the
T-score values obtained from above the distal third of the
radius between this two groups of patients (-1.342 ± 1.378
g/cm2 and -1.551 ± 1.329, p = NS; respectively).
Table I. Main demographical and clinical parameters of patients with coeliac disease (CD), dermatitis herpetiformis (DH) 
and healthy control (HC), expressed as mean ± standard deviations
HC (n = 42) Differences DH (n = 53) Differences CD (n = 34) Differences 
HC vs. DH DH vs. CD HC vs. CD
Age (years) 35.33 ± 10.41 NS 32.18 ± 14.95 NS 38.0 ± 12.1 NS
Body mass index (kg/m2) 24.25 ± 4.08 NS 23.25 ± 5.07 p < 0.01 20.82 ± 2.78 p < 0.01
Postmenopausal (%) 7.1 NS 7.4 NS 8.8 NS
Duration of disease (years) - 10.96 ± 6.53 NS 10.58 ± 8.69
Serum calcium levels (mg/dl) 9.48 ± 0.52 NS 9.64 ± 0.36 p < 0.01 9.34 ± 0.44 NS
Albumin (g/dl) - 4.58 ± 0.33 p < 0.05 4.46 ± 0.52
NS: Non significant differences.
Fig. 1. Bone mineral density of patients with coeliac disease (CD), der-
matitis herpetiformis (DHD) and healthy controls (HC) at lumbar spine,
represented as mean and standard deviations.
Fig. 2. Bone mineral density of patients with coeliac disease (CD), dermatitis
herpetiformis (DHD) and healthy controls (HC) at the femoral neck, repre-
sented as mean and standard deviations (NS: non-significant differences).
Fig. 3. Bone mineral density of patients with coeliac disease (CD), der-
matitis herpetiformis (DHD) and healthy control (HC) at the radius (p:
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A higher ratio of patients had severe villous atrophy with-
in the CD group compared to DH patients, according to
Marsh-Oberhuber grading system (in CD group 3 % of
patients presented stage 0, 9 % stage 1-2, 26 % stage 3a,
15 % stage 3b, and 47 % stage 3c; in DH group, 8 % of
patients exhibited a stage 0, 24 % had stage 1-2, 38 % stage
3a, 13 % stage 3b, and stage 3c was present in 17 % of
patients).
There was a tendency, but no significant difference, to
present a higher BMD in DH patients with normal villous
structure (Marsh-Oberhuber grade 0-2) compared to
patients with villous atrophy (grade 3a-c), being at lumbar
axis 0.985 ± 0,092 vs. 0.997 ± 0,145 g/cm2 (p = NS), at
femoral neck 0.912 ± 0,034 vs. 0.890 ± 0,123 g/cm2 (p =
NS); and at radius 0.757 ± 0,062 vs. 0.686 ± 0,079 g/cm2
(p = NS).
Sixty-two percent of DH patients presented EMA pos-
itive. BMD did not differ in EMA positive compared to
EMA negative DH patients (lumbar axis: 0.795 ± 0.344 vs.
0.885 ± 0.320 g/cm2 [p = NS]; femoral neck: 0.553 ± 0.395
vs. 0.698 ± 0.229 g/cm2 [p = NS]; and radius: 0.551 ± 0.272
vs. 0.608 ± 0.204 g/cm2 [p = NS], respectively).
Correlations between BMD, EMA status and Marsh
stage for enteropathy were not observed.
Serum calcium levels (Ca) were corrected with serum
albumin in every group of subjects. Corrected Ca values
were not significantly different between the DH and CD
groups (10.33 ± 0.48 vs. 9.89 ± 0.71 mg/dl; p = NS). There
was a higher albumin serum concentration in DH compared
to CD patients (4.58 ± 0.33 vs. 4.46 ± 0.52 g/dl, respectively;
p < 0.05), however serum calcium levels differed signifi-
cantly (Table I). A higher phosphorous serum concentration
was also observed in DH compared to CD patients (1.16 ±
0.16 vs. 1.14 ± 0.12 mg/dl; p < 0.01). Patients with CD pre-
sented a lower body mass index (BMI) than that with DH
and HC (p < 0.01). Further parameters regarding the possible
malabsorption status of patients are presented in table I.
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Table II. Osteodensitometric parameters of the subjects with coeliac disease (CD), dermatitis herpetiformis (DH) 
and healthy control (HC), expressed as mean ± standard deviation
Bone mineral density (g/cm2) T-score Z-score
Lumbar region
CD 0.880 ± 0.155 -1.848 ± 1.398 -1.490 ± 1.263
p < 0.01 p < 0.01 p < 0.01
DH 0.993 ± 0.136 -0.855 ± 1.227 -0.509 ± 1.216
p < 0.05 p < 0.05 NS
HC 1.056 ± 0.126 -0.269 ± 1.151 -0.060 ± 1.173
Left femoral neck
CD 0.733 ± 0.151 -1.165 ± 1.295 -0.784 ± 1.131
p < 0.01 p < 0.01 p < 0.01
DH 0.870 ± 0.128 -0.182 ± 1.183 0.224 ± 0.890
NS NS NS
HC 0.841 ± 0.119 -0.211 ± 1.053 0.009 ± 0.984
Non-dominant radius
CD 0.618 ± 0.068 -1.551 ± 1.329 -1.226 ± 1.358
p = 0.01 NS NS
DH 0.670 ± 0.098 -1.342 ± 1.378 -0.751 ± 1.114
NS p < 0.01 NS
HC 0.667 ± 0.072 -0.822 ± 1.106 -0.478 ± 1.122
NS: Non significant differences.
Table III. Distribution of bone mineral density of patients
with coeliac disease (CD), dermatitis herpetiformis (DH) 
and healthy controls (HC) enrolled in our study
Skeletal region Osteoporosis     Osteopenia Normal bone
n (%)                n (%) density n (%)
L2-4 11 (32)             10 (30) 13 (38)
CD FN 9 (26)               8 (24) 17 (50)
R 9 (26)               15 (44) 10 (30)
L2-4 4 (8)                 22 (41) 27 (51)
DH FN 2 (4)                 9 (17) 42 (79)
R 7 (13)               24 (45) 22 (42)
L2-4 2 (5)                 10 (24) 30 (71)
HC FN 2 (5)                 10 (24) 30 (71)
R 0 (0)                 11 (26) 31 (74)
L2-4: lumbar axis 2-4; FN: left femoral neck; R: non-dominant radius.
Thirty three percent of DH patients were not on a GFD.
BMD parameters of non-adherent DH patients did not differ
from those who followed a GFD (lumbar: 0.995 ± 0.152
vs. 1.025 ± 0.111 g/cm2; p = NS; femoral neck: 0.833 ±
0.186 vs. 0.888 ± 0.155 g/cm2; p = NS; and radius: 0.679
± 0.146 vs. 0.670 ± 0.088 g/cm2; p = NS). Mean parathyroid
hormone serum concentrations were within normal ranges
in all groups of subjects.
DISCUSSION
CD and one of its predominantly cutaneous manifesta-
tions, DH are both gluten-sensitive disorders. CD manifests
with intestinal and extraintestinal symptoms with a same
frequency (20,21). Both conditions are mediated by IgA-
class autoantibodies, and an underlying genetic predispo-
sition and environmental factors also play an important
pathophysiological role.
The vast majority of DH patients do not have any abdom-
inal complaint, even when more than 75-90 % of all cases
present histological changes in their small bowel mucosa
similar to those in CD patients: partial or total villous atro-
phy and lymphocytic infiltration of the bowel’s mucous
membrane (2,22).
Although osteopenia as a common complication of CD
is well recognized, only a few data on BMD in DH were
available; up to the present day, the association between
DH and low BMD had been investigated only in three pub-
lished studies (23-25).
Abuzakouk et al. (23) investigated the bone metabolism
of 25 DH patients. The mean duration of the disease was
9 years. Neither BMD nor bone biomarkers were significantly
different in patient and controls. One year long GFD prospec-
tively controlled did not influence the BMD in a subgroup of
patients. Di Stefano et al. (24) included 16 newly diagnosed
DH and sufficient number of CD patients and healthy controls
in their study. BMD was found to be lower in DH compared
to HC, but it was higher than in CD patients. BMD correlated
with BMI and nutritional status, but neither with age at diag-
nosis nor with age at onset of symptoms. BMD was signifi-
cantly higher in DH patients exhibiting partial in contrast to
those with subtotal villous atrophy. Lewis et al. identified 846
DH patients from the General Practice Research Database to
evaluate the risk of bone fracture, malignancy and mortality
among these patients: an increased risk of fracture at hip, fore-
arm or any other bones were not found (25).
We have documented a higher frequency of low bone
mass in patients with DH compared to healthy subjects;
however it was observed to be lower than in CD. There is
no definitive data in the literature regarding the origin of
low BMD in DH. In contrast, the origin of a lowered bone
mass in CD has been show to be multifactorial, being the
most plausible explanations related to enteropathy and a
concomitant malabsorption. In fact, the frequency of symp-
tomatic enteropathy was reported to be lower in DH com-
pared to CD patients (2).
Bone loss of patients suffering gluten sensitive diseases
may depend of the grade of the enteropathy; we observed
an association between the grade of villous atrophy and the
BMD in DH patients, but not reaching statistical signifi-
cance. Villous atrophy correlated to the degree of bone loss
in this Hungarian cohort and also in a recently published
Spanish research: Garcia-Manzanares et al. (26) document-
ed that the degree of bone loss in the lumbar spine correlated
to Marsh stage, moreover, significant differences in major
fracture risk were observed depending on Marsh stage.
However, in a recent study by Abuzakouk et al. (23) this
association between BMD and the severity of enteropathy
graded by the Marsh classification was not observed. Rodri-
go-Sáez et al. have described that a severe villous atrophy
was more frequent in coeliac patients with a younger age
at diagnosis (27). In contrast, an opposite relationship was
documented in a Hungarian cohort, in which the severity
of histology at diagnosis was higher in adults than in chil-
dren (Mars-Oberhuber 3 was presented in 92 % of adults
and 57 % of children) (28). Based on these observations,
one should remind that demographical and geographical
characteristics of the studied populations should be con-
sidered while judging the relationship of enteropathy and
its consequences.
Taking into consideration the previously mentioned con-
flicting results (23,24) additional multicentre studies
enrolling many patients would be needed to clearly deter-
mine how relevant the grade of enteropathy is when assess-
ing BMD in patients with DH.
In our study BMD in DH patients who were not on a
GFD did not differ from those who were on it. Confusing
results on the relationship between GFD and metabolism
have been provided: most of studies demonstrated a lower
prevalence of low BMD in coeliac patients who are on GDF
(16,29), as well as GFD exert a beneficial effect on bone
metabolism of coeliac patients (30-32). A similar prevalence
of low BMD have been documented after one (33) and three
years (34) on GFD, which shows that the main recovery in
bone mass is reached in the first year of following the diet.
Lewis et al. (35) observed that years of exposure to gluten
before diagnosis of CD do not appear to influence BMD
significantly. The relationship between GFD and bone
restoration seems to be more pronounced in paediatric pop-
ulation (36,37): one year long GFD did not improve BMD
in adult population according to the previously mentioned
Irish study (23).
Calcium malabsorption has been suspected to be the
most plausible cause of low BMD in CD (38). In our study
corrected Ca serum levels were not significantly different
between DH and the CD patients, but serum calcium levels
differed significantly. There was a higher albumin serum
concentration in DH patients compared to the CD group.
Additionally, BMI was similar in HC and DH patients,
while it was lower in the studied coeliac population.
Secondary hyperparathyroidism (39) and concomitant
lactase deficiency (40) may also worsen Ca balance in CD.
In fact, reduction of cortical bone mass is very common
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in hyperparathyroidism, which should be tested in all
patients with CD. Parathyroid hormone concentrations
were within the normal range in our patients and bone loss
was prominent in those bones containing mainly trabecular
component.
An increased receptor-associated nuclear factor kappa
ligand/osteoprotegerin ratio has been also detected in newly
diagnosed patients with CD (41); this dissociation causing
uncoupled bone remodelling have been also proved by the
elevation of markers of increased bone turnover in CD
(42,43). Local factors may affect the bone remodelling in
CD as well. Several pro-inflammatory cytokines (inter-
leukin (IL)-1, IL-6, and tumour necrosis factor alpha) are
produced in the intestinal mucosa in CD and result in an
increased osteoclast activity (44). Low levels of other
cytokines, such as IL-12 and IL-18, result in osteoclasto-
genesis due to the lack of the inhibitory effects of these
cytokines (45). Some data show increase serum pro-inflam-
matory cytokine concentrations (IL-8, tumour necrosis fac-
tor alpha) in DH patient (46). Milder degrees of bone loss
in DH compared to CD were observed in our study. We are
not able to explain this phenomenon based on our results.
A more patchy distribution of villous atrophy or a marker
cytokine alteration in CD compared to DH may be hypoth-
esized in order to explain this phenomenon; however, these
comparisons have been never performed until now.
A loss of bone density in the peripheral skeleton may
persist despite normalization of lumbar and femoral bone
density after patients are on a GFD. The importance of an
early diagnosed of metabolic bone disease is clear in CD.
The proper diagnostic workup and strict GFD is mandatory
to prevent bone fractures, but timing of densitometry in the
follow up has not been clarified, but to measure BMD after
the first year on a GFD has been recommended proposed
as useful.
Our results suggest the usefulness of measuring the bone
density of DH patients, but doubts on the appropriate timing
for the first bone density scan, the diagnostic workup and
the most appropriate therapy for DH patients with a low
BMD remain.
There are some limitations of our study. More complete
and accurate information would have been achieved from
in a greater number of patients, but we should remain that
the incidence of DH has been estimated to be 8-16 times
lower than that of CD (47,48). So, to the best of our knowl-
edge, this study investigated BMD in the widest number
of DH cases up to now. We did not examine more sophis-
ticated laboratory parameters, as biomarkers related to bone
formation and resorption, or cytokines. The exact role of
these markers has not clarified in the diagnostic workup of
gastrointestinal disorders involved with bone metabolism.
Further investigation on this biomarkers will help to under-
stand the pathogenesis of DH-associated bone loss.
As a conclusion, bone mineral content in patients with
DH was significantly lower than in healthy controls, but
higher than in CD. Bone mineral loss was more prominent
in bones containing more trabecular than cortical compo-
nent. This phenomenon suggests a similar pathogenetic ori-
gin for DH and CD-associated osteopenia and osteoporosis,
even when a relationship between the severity of villous
atrophy and bone loss was not clearly shown. Further
research will define a proper diagnostic and therapeutic
algorithm for the management of DH.
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